

## DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated next to my name. I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **Angiotensin Converting Enzyme Inhibitor Use For Treatment And Prevention Of Gastrointestinal Disorders**, the specification of which is attached hereto. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor: **Daniel H. Teitelbaum**

Inventor's Signature: _____	Date: _____
Residence: <u>5887 Lohr Lake Drive, Ann Arbor MI 48108</u>	Citizenship: <u>United States of America</u>
Post Office Address: <u>5887 Lohr Lake Drive, Ann Arbor MI 48108</u>	

Full Name of Second Joint Inventor: **Barbara E. Wildhaber**

Inventor's Signature: _____	Date: _____
Residence: <u>14 ch. des Boqueteaux 255 Veyrier, Geneva, Switzerland</u>	Citizenship: <u>Switzerland</u>
Post Office Address: <u>14 ch. des Boqueteaux 255 Veyrier, Geneva, Switzerland</u>	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Daniel H. Teitelbaum *et al.* Group No.:  
Serial No.: Examiner:  
Filed:  
Entitled: **Angiotensin Converting Enzyme Inhibitor Use For Treatment And  
Prevention Of Gastrointestinal Disorders**

## POWER OF ATTORNEY BY ASSIGNEE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The Regents of the University of Michigan, as Assignee of record of the entire interest of the above-identified patent application, hereby appoints the members of the firm of MEDLEN & CARROLL, LLP, a firm composed of:

Tanya A. Arenson	(Reg. No. 47,391)	Robert A. Goetz	(Reg. No. P-55,210)
Donald A. Baricevac	(Reg. No. 44,021)	Maha A. Hamdan	(Reg. No. 43,655)
Jason R. Bond	(Reg. No. 45,439)	Thomas C. Howerton	(Reg. No. 48,650)
Mary Ann D. Brow	(Reg. No. 42,363)	J. Mitchell Jones	(Reg. No. 44,174)
Thomas W. Brown	(Reg. No. 50,002)	Christine A. Lekutis	(Reg. No. 51,934)
Peter G. Carroll	(Reg. No. 32,837)	James C. Mason	(Reg. No. 50,255)
David A. Casimir	(Reg. No. 42,395)	David J. Wilson	(Reg. No. 45,225)

as its attorneys with full power of substitution to prosecute this application and transact all business in the Patent and Trademark Office in connection therewith.

Please direct all future correspondence and telephone calls regarding this application to:

David A. Casimir  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105

Telephone: 608/218-6900  
Facsimile: 608/218-6910

I hereby certify that the Assignment document filed with the application, or filed subsequent to the filing date of the application, has been reviewed and I hereby certify that, to the best of my knowledge and belief, title is with The Regents of the University of Michigan.

**Dated:** \_\_\_\_\_

By: Ruth L. Rasor  
Director of Licensing, UM Technology Transfer  
The Regents of the University of Michigan  
3003 S. State Street, Suite 2071  
Ann Arbor, Michigan 48109-1280